Lenalidomide
| Clinical data | |
|---|---|
| Pronunciation | /ˌlɛnəˈlɪdoʊmaɪd/ |
| Trade names | Revlimid, Linamide, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Undetermined |
| Protein binding | 30% |
| Metabolism | Undetermined |
| Elimination half-life | 3 hours |
| Excretion | Kidney (67% unchanged) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.218.924 |
| Chemical and physical data | |
| Formula | C13H13N3O3 |
| Molar mass | 259.265 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
SMILES
| |
InChI
| |
| (verify) | |
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS).[7] For multiple myeloma, it is a first-line treatment, and is given with dexamethasone.[7] It is taken by mouth.[7]
Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping.[7] Severe side effects include low blood platelets, low white blood cells, and blood clots.[7] The dose may need to be adjusted in people with kidney problems.[7] Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus.[7]
Lenalidomide belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs) or Cereblon E3 ligase modulators, which includes thalidomide and its analogs.[8] In lymphocytes, these drugs target an E3 ubiquitin ligase and change its specificity to include new targets.[8] This results in the rapid degradation of several disease-related proteins including IKZF1, IKZF3, and CSNK1A1.[8]
Lenalidomide was approved for medical use in the United States in 2005.[7] It is on the World Health Organization's List of Essential Medicines.[9]
- ^ "Lenalidomide (Revlimid) Use During Pregnancy". Drugs.com. 13 March 2020. Archived from the original on 9 October 2020. Retrieved 13 August 2020.
- ^ "LENALIDOMIDE VIATRIS (Alphapharm Pty Ltd)". Department of Health and Ages Care. Archived from the original on 13 November 2022. Retrieved 1 April 2023.
- ^ "Lenalidomide Sun/Lenalidomide Rbx/Lenalidomide Ran (Sun Pharma ANZ Pty Ltd)". Department of Health and Ages Care. Archived from the original on 18 March 2023. Retrieved 1 April 2023.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
- ^ Cite error: The named reference
PI2019was invoked but never defined (see the help page). - ^ "Revlimid EPAR". European Medicines Agency. 14 June 2007. Retrieved 2 July 2024.
- ^ a b c d e f g h "Lenalidomide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2016. Retrieved 27 October 2019.
- ^ a b c Fink EC, Ebert BL (November 2015). "The novel mechanism of lenalidomide activity". Blood. 126 (21): 2366–2369. doi:10.1182/blood-2015-07-567958. PMC 4653765. PMID 26438514.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.